The New England Journal of Medicine, just published the results of the Checkmate 025 phase III study, presented in part at the European Cancer Congress 2015 in Vienna.
September 25, 2015. Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase III study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment.
Please read the full article in The New England Journal of Medicine: